Mammary Cell News Volume 5.28 | Jul 18 2013

Reduced Formation of Depurinating Estrogen-DNA Adducts by Sulforaphane or KEAP1 Disruption in Human Mammary Epithelial MCF-10A Cells
Sulforaphane (SFN) may alter estrogen metabolism and thus protect against estrogen-mediated DNA damage and carcinogenesis. Human breast epithelial MCF10A cells were treated with either vehicle or SFN and either estradiol (E2) or its metabolite 4-OHE2. 4-Hydroxy derived estrogen metabolites and depurinating DNA adducts formed from E2 and its interconvertable metabolite estrone were analyzed by mass spectrometry. [Carcinogenesis] Abstract

Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells
Investigators report a small molecule compound YK-3-237 that reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer cells carrying mtp53. YK-3-237 activates SIRT1 enzyme activities in vitro and deacetylation of both mtp53 and wild type p53 in a SIRT1-dependent manner. [Oncotarget] Abstract

DAX-1, as an Androgen-Target Gene, Inhibits Aromatase Expression: A Novel Mechanism Blocking Estrogen-Dependent Breast Cancer Cell Proliferation
The authors demonstrated, in hormone-dependent breast cancer cells, the existence of a functional interplay between the androgen receptor, the orphan nuclear receptor DAX-1 and the aromatase enzyme involved in the inhibition of the estrogen-dependent breast cancer cell proliferation exerted by androgen signaling. [Cell Death Dis] Full Article

Identification of Sirtuin 3, a Mitochondrial Protein Deacetylase, as a New Contributor to Tamoxifen Resistance in Breast Cancer Cells
Scientists showed that Sirtuin 3 (SIRT3) was significantly up-regulated at both mRNA and protein levels in the tamoxifen (Tam)-resistance human breast cancer cell line MTR-3, which was derived from MCF-7 line by continuous selective culture in the presence of 1 μM of Tam for two years. They further demonstrated that SIRT3 was rapidly up-regulated in the sensitive MCF-7 cells following exposure to Tam. [Biochem Pharmacol] Abstract

Quantitative Proteomic Analysis of HER2 Normal and Overexpressing MCF-7 Breast Cancer Cells Revealed Proteomic Changes Accompanied with HER2 Gene Amplification
Researchers studied the proteomic changes that accompany the HER2 gene amplification to identify potential new therapeutic targets and biomarkers. They analyzed bio-triplicate proteome samples extracted from wild-type MCF-7 human breast cancer cells and their isogenic stably overexpressing HER2 (amplified) transfectants. [J Proteomics] Abstract

Steroidal Aromatase Inhibitors Inhibit Growth of Hormone-Dependent Breast Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis
Scientists evaluated the effects of several steroidal aromatase inhibitors, namely 3β-hydroxyandrost-4-en-17-one, androst-4-en-17-one, 4α,5α-epoxyandrostan-17-one and 5α-androst-2-en-17-one, on cell proliferation, cell cycle progression and cell death in an estrogen receptor positive aromatase-overexpressing human breast cancer cell line. [Apoptosis] Abstract

Curcumin Enhances TRAIL-Induced Apoptosis of Breast Cancer Cells by Regulating Apoptosis-Related Proteins
Researchers found that the combination of TNF-related apoptosis inducing ligand (TRAIL) with curcumin can synergistically induces apoptosis in three TRAIL-resistant breast cancer cell lines. The mechanism behind this synergistic cell death was investigated by examining an effect of curcumin on the expression and activation of TRAIL-associated cell death proteins. [Mol Cell Biochem] Abstract

Estrogen Induced Concentration Dependent Differential Gene Expression in Human Breast Cancer (MCF7) Cells: Role of Transcription Factors
Meta-analysis of the expression data of MCF7 cells treated with low or high dose of estradiol was performed. Investigators identified genes differentially expressed at the low or the high dose, and examined the nature of regulatory elements in the vicinity of these genes. [Biochem Biophys Res Commun] Abstract

CLINICAL RESEARCH

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
Scientists performed a randomized phase III trial comparing sunitinib plus capecitabine (2,000 mg/m2) with single-agent capecitabine (2,500 mg/m2) in patients with heavily pretreated metastatic breast cancer. [J Clin Oncol] Abstract

Circulating Tumor Cells Predict Progression-Free and Overall Survival in Chinese Patients with Metastatic Breast Cancer, HER2-Positive or Triple-Negative (CBCSG004): A Multicenter, Double-Blind, Prospective Trial
This study evaluated the potential utility of circulating tumor cell measurements in predicting responses to anticancer therapies, including response to human epidermal growth factor receptor-2 (HER-2)-targeted agents, progression-free survival, and overall survival in Chinese women with metastatic breast cancer. [Ann Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
Rexahn Pharmaceuticals, Inc. announced that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems. This technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. The direct delivery of chemotherapeutic drugs into the tumors has been shown to result in increased efficacy and reduced toxicity. [Rexahn Pharmaceuticals, Inc.] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR^TM can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Fellow – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Breast Cancer Cell Research (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Fellow – Breast and Renal Cell Carcinoma Research (University of North Carolina – Chapel Hill)

Postdoctoral Position – Breast and Ovarian Cancer Biology (University of Pennsylvania School of Medicine)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow – Cancer Genes in Breast Cancer (MD Anderson Cancer Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.